Inna Ablyaeva
Family · Scottsdale, AZNPI 1134600133
Payments from drug & device makers
Across 227 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$824
- United Therapeutics Corporation$732
- Actelion Pharmaceuticals US, Inc.$469
- Grifols USA, LLC$382
- Intuitive Surgical$225
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,45698%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,233 |
| GSK | 41 | $824 |
| United Therapeutics Corporation | 22 | $732 |
| Actelion Pharmaceuticals US, Inc. | 12 | $469 |
| Grifols USA, LLC | 13 | $382 |
| Intuitive Surgical | 1 | $225 |
| Sanofi | 8 | $223 |
| Regeneron Healthcare Solutions, Inc. | 7 | $207 |
| Merck | 12 | $205 |
| Inari Medical, Inc. | 1 | $193 |
| Astellas Pharma US Inc | 4 | $177 |
| Amgen | 9 | $158 |
| Boehringer Ingelheim | 7 | $152 |
| Viiv Healthcare Company | 5 | $145 |
| Lilly USA, LLC | 3 | $136 |
| Jazz Pharmaceuticals Inc. | 6 | $131 |
| UCB, Inc. | 4 | $116 |
| Mylan Specialty L.p. | 5 | $105 |
| Viatris Specialty LLC | 4 | $104 |
| Verona Pharma, Inc. | 3 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Covis Pharma GmbH | 2 | $64 |
| Electromed, Inc. | 7 | $60 |
| CSL Behring | 2 | $51 |
| Vifor Pharma, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $37 |
| Gilead | 2 | $33 |
| Baxter Healthcare | 2 | $33 |
| Insmed, Inc. | 2 | $30 |
| Pfizer | 1 | $25 |
| Novartis | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| CMP Pharma, Inc. | 1 | $21 |
| Napo Pharmaceuticals Inc | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$346
- TEZSPIRE$346
- BREZTRI$244
- Da Vinci Surgical System$225
- FASENRA$221
- FLOWTRIEVER CATHETER, S$193
- CT THROMBECTOMY SYSTEM KIT$193
- UPTRAVI$150
- OPSUMIT$150
- Prolastin-C Liquid$113
How this compares
$6,570 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 534 | $434,211 |
| OfevNintedanib Esylate | 21 | $275,695 |
| Breo ElliptaFluticasone/Vilanterol | 130 | $64,725 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $55,020 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $32,184 |
| Spiriva RespimatTiotropium Bromide | 35 | $22,976 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $14,616 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,518 |
| XareltoRivaroxaban | 19 | $12,688 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $11,478 |
| Spiriva HandihalerTiotropium Bromide | 16 | $10,795 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,158 |
| EliquisApixaban | 11 | $7,516 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $6,897 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $6,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $824 | $552,396766 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $152 | $310,14982 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $1,233 | $82,321155 claims |
| PfizerEliquis | $25 | $7,51611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Scottsdale
- Kaitlyn LouchheimScottsdale$208K
- Jennifer PrinceScottsdale$76K
- Camilla BinksScottsdale$62K
- Jessica TapiaScottsdale$36K
- Dawn MougelScottsdale$34K
- Keegan RussellScottsdale$28K
- Jamie HowardScottsdale$14K
- Anna CramerScottsdale$14K
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.